David Lebowitz
Stock Analyst at Citigroup
(4.2)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IONS Ionis Pharmaceutical... | Maintains: Strong Buy | 69 84 | 61 | 37.7% | 14 | Sep 3, 2025 | |
CYTK Cytokinetics | Maintains: Strong Buy | 77 84 | 52.09 | 61.26% | 4 | Sep 2, 2025 | |
CLDX Celldex Therapeutics | Maintains: Buy | 56 48 | 23.4 | 105.13% | 2 | Aug 20, 2025 | |
SDGR Schrodinger | Downgrades: Neutral | 35 20 | 19.44 | 2.88% | 10 | Aug 15, 2025 | |
ASND Ascendis Pharma | Maintains: Strong Buy | 243 290 | 205.22 | 41.31% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 88 103 | 86.56 | 18.99% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 31 38 | 25.48 | 49.14% | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 15 22 | 12.68 | 73.5% | 4 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 58 67 | 54.29 | 23.41% | 5 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 83 129 | 129.46 | -0.36% | 6 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 45 56 | 37.69 | 48.58% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 14 10 | 11.84 | -15.54% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 1.73 | -13.29% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 32 45 | 56.95 | -20.98% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 68 | 77.39 | -12.13% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 453.8 | -15.82% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 56.38 | 70.27% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 5.95 | 101.68% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 455.03 | -63.96% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 17.33 | 125.04% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 16.33 | 28.6% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 435 405 | 6.25 | 6380% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 1.13 | 1138.94% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | 1.4 | 21328.57% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | 1.47 | 240.14% | 2 | Aug 10, 2021 |